Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Recurrence × trastuzumab deruxtecan × Clear all

Phase

Status

Recruiting 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 6 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Neoplasms 2 Recurrence 1 Ovarian Neoplasms 1 HER2 Overexpression 1 Colorectal Neoplasms 1 Breast Cancer With Brain Metastasis 1 Brain Neoplasms 1 Advanced Solid Tumor 1

Interventions

fludarabine 4 Bevacizumab 4 toripalimab 3 Paclitaxel 3 Etoposide 3 Cyclophosphamide 3 Carboplatin 3 zimberelimab 2 glumetinib 2 Platinum 2 Immunotherapy, Adoptive 2 Gemcitabine 2 Drug Therapy 2 Docetaxel 2 Cisplatin 2 Capecitabine 2 zanubrutinib 1 venetoclax 1 trastuzumab deruxtecan 1 sintilimab 1 sargramostim 1 relmacabtagene autoleucel 1 pelcitoclax 1 osimertinib 1 lenvatinib 1 glofitamab 1 gallium maltolate 1 eribulin 1 cemiplimab 1 capivasertib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07340164 2026-01-14

TROY

Yonsei University

Phase 2 Not yet recruiting

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡